Review
PD-1/PD-L1 and CTLA-4 monoclonal antibodies: gastrointestinal toxicity and treatment
Fei Yue, Ren Xiubao, Wang Xianhuo, Zhang Huilai
Published 2019-10-31
Cite as Chin J Microbiol Immunol, 2019,39(10): 794-799. DOI: 10.3760/cma.j.issn.0254-5101.2019.10.012
Abstract
PD-1/PD-L1 (programmed cell death 1/programmed cell death 1 ligand 1) and CTLA-4 (cytotoxic T lymphocyte antigen 4) are currently approved major immune checkpoints. Immune checkpoint inhibitors against them are novel monoclonal antibodies that perform well in a variety of malignancies such as melanoma, renal cell carcinoma, non-small-cell lung cancer, urothelial carcinoma and Hodgkin′s lymphoma. However, with the increasing use of immune checkpoint inhibitors, immune-related adverse events cannot be ignored. The incidence of gastrointestinal toxicity is second only to skin toxicity. In this review, we focused on the mechanisms of these immune checkpoint inhibitors and the characteristics of gastrointestinal toxicity induced by them, and also discussed the clinical management strategies.
Key words:
Immune checkpoint inhibitor; Gastrointestinal toxicity
Contributor Information
Fei Yue
Department of Lymphoma, Tianjin Medical University Cancer Hospital, Sino-US Center for Lymphoma Diagnosis and Treatment, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin′s Clinical Research Center for Cancer, Tianjin 300060, China
Ren Xiubao
Department of Lymphoma, Tianjin Medical University Cancer Hospital, Sino-US Center for Lymphoma Diagnosis and Treatment, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin′s Clinical Research Center for Cancer, Tianjin 300060, China
Wang Xianhuo
Department of Lymphoma, Tianjin Medical University Cancer Hospital, Sino-US Center for Lymphoma Diagnosis and Treatment, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin′s Clinical Research Center for Cancer, Tianjin 300060, China
Zhang Huilai
Department of Lymphoma, Tianjin Medical University Cancer Hospital, Sino-US Center for Lymphoma Diagnosis and Treatment, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin′s Clinical Research Center for Cancer, Tianjin 300060, China